Stem cell therapy could free type 1 diabetes patients from insulin injections

NCT ID NCT04786262

Recruiting now Disease control Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated May 24, 2026 · Updated 13 times

Summary

This study tests a new stem cell treatment called VX-880 for people with type 1 diabetes who have dangerous low blood sugar episodes. The goal is to see if a single infusion can help the body make its own insulin again, reducing or eliminating the need for insulin shots. About 52 adults with long-standing type 1 diabetes will take part. The treatment is given as an infusion along with immune-suppressing drugs to protect the new cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Baylor Scott and White Research Institute
RECRUITING

Dallas, Texas, 75246, United States
CHU Lille
RECRUITING

Lille, France
Cardiovascular, Metabolic Medicine and Sciences, King's College London
RECRUITING

London, United Kingdom
Centre de recherche en Biomédecine de Strasbourg
RECRUITING

Strasbourg, France
Churchill Hospital
RECRUITING

Headington, Oxford, United Kingdom
City of Hope
RECRUITING

Duarte, California, 91010, United States
Dresden Center for Islet Transplantation
RECRUITING

Dresden, Germany
Hopiteaux Universitaires de Geneve
RECRUITING

Geneva, Switzerland
Hospital of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
IRCCS Ospedale San Raffaele
RECRUITING

Milan, Italy
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology
RECRUITING

Riyadh, Saudi Arabia
King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology
RECRUITING

Riyadh, Saudi Arabia
Leiden University
RECRUITING

Leiden, Netherlands
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
McGill University Health Centre
RECRUITING

Montreal, Canada
Northwestern Organ Transplant Center
COMPLETED

Chicago, Illinois, 60611, United States
Oslo University Hospital
RECRUITING

Oslo, Norway
Royal Infirmary of Edinburgh
RECRUITING

Edinburgh, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
RECRUITING

Newcastle upon Tyne, United Kingdom
Toronto General Hospital (TGH)
RECRUITING

Toronto, Canada
UHealth Diabetes Research Institute
RECRUITING

Miami, Florida, 33136, United States
University of Alberta, Edmonton
RECRUITING

Edmonton, Canada
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Pittsburgh Medical Center Montefiore
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792, United States
VCU Medical Center, Richmond
RECRUITING

Richmond, Virginia, 23298, United States
Vancouver General Hospital
RECRUITING

Vancouver, Canada

Conditions

Explore the condition pages connected to this study.

DIABETES MELLITUS, TYPE 1 IMPAIRED HYPOGLYCEMIC AWARENESS SEVERE HYPOGLYCEMIA